ARMEN GARO H purchased $13K of PTIX
ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 20,000 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.65 on 2026-08-21.
Protagenic Therapeutics, Inc.\new
No enriched coverage for $PTIX in the last 7 days.
ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 20,000 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.65 on 2026-08-21.
ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 16,634 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.59 on 2026-08-20.
ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 2,700 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.35 on 2026-08-19.
Recent PTIX coverage spans insider activity, regulation and financial news.
In the last 30 days, PTIX insiders filed 7 SEC Form 4 transactions — 7 purchases ($31K) and no sales. The most active reporter was ARMEN GARO H, EXEC. CHAIR & PRINCIPAL OFF, with 6 filings.
Small insider buy may signal confidence but limited material impact.
Small insider purchase signals confidence but size is modest; unlikely to move price materially.
Small insider purchase signals modest confidence but limited market impact due to low transaction size.
Positive regulatory feedback reduces execution risk and may trigger a price rally ahead of the IND filing.
This is a routine Form 4 insider buy with small dollar value, offering limited incremental signal on near-term fundamentals.
alphai scores every news story that mentions PTIX with an AI model for sentiment and relevance, and aggregates insider trades from Protagenic Therapeutics, Inc.\new's SEC EDGAR Form 4 filings. Figures refresh continuously.
ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 20,000 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.65 on 2026-08-21.
1 min readARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 16,634 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.59 on 2026-08-20.
1 min readARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 2,700 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.35 on 2026-08-19.
1 min readProtagenic Therapeutics (PTIX) received FDA feedback supporting its planned Phase 1 program for PT00114, a treatment for generalized anxiety disorder. The FDA raised no objections to the program design, dose-escalation approach, or CMC and nonclinical packages. The company plans to submit the IND before the end of 2026 and target first patient dosing in the first half of 2027. PT00114 has shown promising results in preclinical and early-phase studies.
2 min readARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 2,220 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.32 on 2026-08-11.
1 min readARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 685 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.22 on 2026-08-06.
1 min readARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 5,000 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.26 on 2026-08-05.
2 min readInvesting.com reported Monday’s SEC Form 4 insider trades for several US-listed firms. Buys included Hanover Bancorp (HNVR) President Kevin O’Connor buying 10,000 shares at $26.88, Protagenic Therapeutics (PTIX) executive chair buying 26,291 shares at $0.1828, and V F Corp (VFC) CEO buying 32,894 shares at ~$14.98. Sales included Snowflake (SNOW) EVP selling 29,986 shares at $300 and Cactus (WHD) leaders selling 86,700 shares each at $57.618.
7 min readARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF.) purchased 26,291 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.18 on 2026-07-30.
1 min read^ Original-Research: Pentixapharm Holding AG - from NuWays AG 31.07.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.
4 min read